Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could your morning coffee slow Huntington's?

NCT ID NCT03034122

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether caffeine intake is linked to how Huntington's disease progresses in people who have the gene but not yet symptoms. Researchers followed 77 participants, measuring brain volume changes and thinking skills over time. The goal was to see if caffeine might be a simple lifestyle factor that could influence the disease.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
caffeine (dietary)
What this could lead to
If caffeine is found to slow brain changes, it could point toward a simple dietary way to delay Huntington's symptoms.
What could go wrong
This is a small observational study, not a treatment trial. It cannot prove cause and effect, and results may not apply to everyone with Huntington's.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

77 people

The number who actually took part.

Started

Oct 2017

Finished

Apr 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

premanifest HD subjects

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * HD mutation carriers (\>36 CAG) * premanifest (total motor UHDRS \< 5) * estimated time to diagnosis between 3 and 10 years * adults older than 21 years (in order to exclude juvenile patients who begin the disease before 21 years) * informed consent signed * with a social protection Exclusion Criteria: * MRI contraindication * pregnant and lactating women * People under guardianship, trusteeship, deprive of freedom

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Huntington disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Huntington disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Huntington disease

Contacts and locations

Locations

  • AH-HP La Pitié-Salpétrière

    Paris, 75679, France

  • AH-HP, Hôpital Henri Mondor

    Paris, France

  • CHU Montpellier

    Montpellier, France

  • CHU Pellegrin

    Bordeaux, France

  • CHU Purpan

    Toulouse, France

  • CHU de Amiens

    Amiens, France

  • CHU de Angers

    Angers, France

  • CHU de Grenoble

    Grenoble, France

  • CHU de Nancy

    Nancy, France

  • Hôpital Roger Salengro, CHRU

    Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.